Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza

International Journal of Medical Sciences

Volumn 9, Issue 2, 2012, Pages 157-162

  Darwish, Ilyse ^a,b   Miller, Chris ^c   Kain, Kevin C ^a,b   Liles, W Conrad ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Influenza A WSN 33; Nitric oxide; Severe influenza

Indexed keywords

NITRIC OXIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; QUANTITATIVE STUDY; SURVIVAL RATE; VIRUS INHIBITION; VIRUS LOAD; VIRUS STRAIN; WEIGHT REDUCTION;

ADMINISTRATION, INHALATION; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MICE; MICE, INBRED C57BL; NITRIC OXIDE; ORTHOMYXOVIRIDAE INFECTIONS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; VIRAL LOAD;

EID: 84863406071     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.3880     Document Type: Article

References (38)

1. [Internet] WHO: Geneva, Switzerland. Fact sheet 211, Influenza http://www.who.int/mediacentre/factsheets/fs211/en/
2. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008; 52: 3284-92.
3. [Internet] CDC. 2008-2009 Influenza season week 39 ending October 3, 2009. http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/weekly39.htm
4. [Internet] WHO: Geneva, Switzerland. Influenza A (H1N1) virus resistance to oseltamivir. http://www.who.int/influenza/resources/documents/H1N1webupdate20090318_ed_ns.pdf
5. [Internet] WHO: Geneva, Switzerland. Weekly update on oseltamivir resistance to influenza H1N1 (2009) viruses.http://www.who.int/influenza/2011_02_11_weekly_web_update_oseltamivir_resistance.pdf
6. [Internet] WHO: Geneva, Switzerland. Weekly epidemiological record. 2011; 86: 81-92.http://www.who.int/wer/2011/wer8610.pdf
7. Le QM, Kiso M, Someya K, et al. Avian flu: Isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108.
8. De Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005; 353: 2667-72.
9. Sheu TG, Fry AM, Garten RJ, et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A (H1N1) viruses: 2008-2010. J Infect Dis. 2011; 203: 13-17.
10. Murphy BR, Baron S, Chalhub EG, Uhlendorf CP, Chanock RM. Temperature-sensitive mutants of influenza virus. IV. Induction of interferon in the nasopharynx by wild-type and a temperaturesensitive recombinant virus. J Infect Dis. 1973; 128: 488-93.
11. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003; 51: 123-29.
12. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: A case series. Lancet 2008; 372: 744-49.
13. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009; 361: 1935-44.
14. To K, Hung I, Li I, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010; 50: 850-59.
15. Kumar A. Early versus late oseltamivir treatment in severly ill patients with 2009 pandemic influenza A (H1N1): speed is life. J Antimicrob Chemother. 2011; 66: 959-63.
16. Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001; 2: 907-16.
17. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies (Review). Nat Rev Microbiol. 2004; 2: 820-32.
18. Fang FC, De Groote MA. NO inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis. 1995; 21: S162-5.
19. Akerstrom S, Mousavi-Jazi M, Klingstrom J, Leijon M, Lundkvist A, Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005; 79: 1966-69.
20. Rimmelzwaan G, Baars M, Lijster P, Fouchier R, Osterhaus A. Inhibition of influenza virus replication by nitric oxide. J Virol. 1999; 73: 8880-3.
21. Karupiah G, Xie QW, Buller RML, et al. Inhibition of viral replication by IFNg induced NO synthase. Science 1993; 261: 1445-8.
22. Croen KD. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J Clin Invest. 1993; 91: 2446-52.
23. Chen L, Liu P, Gao H, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis. 2004; 39: 153135.
24. Napolitano LM, Park PK, Raghavendran K, Bartlett RH. Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure. Crit Care Med. 2010; 38: e74-90.
25. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009; 302: 1872-79.
26. Food and Drug Administration. Approval of NDA 20-846 INOmax nitric oxide gas. USA: FDA. 1999.
27. DiBlasi RM, Myers TR, Hess DR. Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure. Respir Care 2010; 55: 1717-45.
28. McMullin B, Chittock D, Roscoe D, Garcha H, Wang L, Miller C. The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the ICU. Resp Care 2005; 50: 1451-56.
29. Miller C, McMullin B, Ghaffari A, Miller J, Stenzler A, Pick N, Roscoe D, Ghahary A, Road J, Av Gay Y. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric Oxide 2009; 20: 16-23.
30. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical inhaled nitric oxide research group. N Engl J Med. 2000; 342: 469-74.
31. The Franco-Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet 1999; 354: 1066-71.
32. Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2010; 12:CD000509.
33. Donohue PK, Gilmore MM, Cristofalo E, et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011; 127: e414-22.
34. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults: a meta-analysis. Anesth Analg. 2003; 1: CD002787.
35. Adhikari NKJ, Burns KEA, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ. 2007; 334: 779.
36. Afshari A, Brok J, Møller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth Analg. 2011; 112: 1411-21.
37. Meade MO, Jacka MJ, Cook DJ, et al. Survey of interventions for the prevention and treatment of acute respiratory distress syndrome. Crit Care Med. 2004; 32: 946-54.
38. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multi-center study. The I-NO/PPHN Study Group. Pediatrics 1998; 1: 325-34.